Tempus AI (NASDAQ:TEM) CEO Ryan Fukushima Sells 10,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 10,000 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the transaction, the chief executive officer directly owned 201,047 shares of the company’s stock, valued at $12,062,820. The trade was a 4.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50.

Tempus AI Trading Down 4.7%

NASDAQ TEM traded down $2.82 on Wednesday, reaching $57.27. The company had a trading volume of 4,732,815 shares, compared to its average volume of 5,979,971. The firm has a market cap of $10.28 billion, a price-to-earnings ratio of -33.30 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The business has a 50 day moving average of $50.82 and a two-hundred day moving average of $54.38.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.24) EPS. Analysts forecast that Tempus AI, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Tempus AI

Hedge funds have recently modified their holdings of the stock. JPL Wealth Management LLC acquired a new stake in Tempus AI in the third quarter worth $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at about $27,000. Harvest Fund Management Co. Ltd bought a new position in shares of Tempus AI during the 3rd quarter worth about $38,000. Danske Bank A S bought a new position in shares of Tempus AI during the 3rd quarter worth about $48,000. Finally, Sunbelt Securities Inc. bought a new stake in Tempus AI in the 3rd quarter valued at about $52,000. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

TEM has been the subject of a number of recent analyst reports. TD Cowen increased their target price on shares of Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. HC Wainwright dropped their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. BTIG Research reiterated a “buy” rating and set a $80.00 price objective on shares of Tempus AI in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Hold” and an average target price of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.